Drug Profile
Betamethasone oral spray - Acasti Pharma
Alternative Names: Betamethasone - Acasti Pharma; GTX 102; GTX102 - Acasti PharmaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Grace Therapeutics
- Developer Acasti Pharma
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Ataxia telangiectasia
Most Recent Events
- 14 Mar 2023 Acastic pharma plans a Type B meeting with FDA in second half of 2023 (Acastic pharma pipeline, March 2023)
- 29 Dec 2022 Preliminary topline pharmacokinetics and adverse event data from a phase I trial in Ataxia Telangiectasia released by Acasti Pharma .
- 28 Dec 2022 Acasti Pharma plans a phase III trial for Ataxia Telangiectasia in Second half of 2023